Mizuho analyst Graig Suvannavejh raised the firm’s price target on Harmony Biosciences (HRMY) to $39 from $36 and keeps an Outperform rating on the shares following the Q3 report. The firm cites the strong Wakix performance for the target increase.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- Harmony Biosciences Holdings: Strong Q3 Performance and Growth Potential Justify Buy Rating
- Harmony Biosciences Reports Strong Q3 2025 Results
- Harmony Biosciences Q3 Earnings Call Highlights Robust Growth
- Promising Outlook for Harmony Biosciences: Buy Rating Affirmed Due to Strong Product Momentum and Pipeline Progress
- Harmony Biosciences price target raised to $32 from $31 at BofA